Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD

Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD

Bibliographic Details
Main Authors: Henrik Birn, Jeppe Hagstrup Christensen, Frederik Husum Mårup, Christian Daugaard Peters
Format: Article
Language:English
Published: BMJ Publishing Group 2022-02-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/2/e057503.full

Internet

https://bmjopen.bmj.com/content/12/2/e057503.full

Similar Items